One of your key points was that the “missense variants of unknown significance (VUS) represent a large and growing problem.” Why is this and how does your answer relate to the “bold prediction” of the seminar, “The clinical relevance of all encountered genomics will be readily predicable, rendering the diagnostic designation VUS obsolete? VUS are a large and growing problem…
Read More
Seattle-based biotech Alpine Immune Sciences announced Wednesday it is raising roughly $91 million, before expenses, through a private placement. The biotech is expanding its pipeline and developing two of its drugs with the private placement, a means for companies to raise money by selling shares to select investors. Alpine expects the private placement to close “on or about” Friday. Frazier…
Read More
A study published today in the journal Cell Host & Microbe reported that the increased presence of certain bacteria in a gut biome indicates a greater likelihood that colon polyps will become cancerous. In his research, William DePaolo, associate professor at the University of Washington School of Medicine, tracked 40 patients who had undergone routine colonoscopies and had biopsies taken…
Read More
It wasn’t an easy hunt. No fun scavenger clues on the way. This human brain cell, still alive, was buried near the very bottom of a thin slice of the many-layered cortex, the wrinkled outermost shell of the brain. The fifth layer of the cortex, where the scientist’s target lived, is chock-full of myelin, the tough white support material that…
Read More
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today presented interim clinical results from a Phase 1/1b clinical study of SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing…
Read More